Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APG777 in Moderate-to-severe Atopic Dermatitis
2024-511260-84-00Phase 2Authorised
- Sponsor
- Apogee Therapeutics
- Start
- Sep 2024
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing APG777 with Placebo (2 arms). Primary endpoints: Part A: Percent Change from Baseline in Eczema Area and Severity Index (EASI) at Week 16 and Part B: Proportion of patients who achieve EASI 75 at Week 16. Planned start Sep 2024; status: authorised.
02
Drugs
apg777
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2024-511260-84-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511260-84-00.